Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fudan Univ. TLR2 compound B10
- Development stage
- Unknown
- Lead developer
- Fudan University
01
Overview
Fudan Univ. TLR2 compound B10: sourced facts only. name: "Among them, diastereomer B10 and B12 substituted (S)-2-phenylcyclopropylamide side chain of Diprovocim with simple (R)- and (S)-n-butyl groups exhibited comparable TLR2 agonistic activities with EC50 values of 35 nM and 39 nM, respectively." [PMID:36174413]; target: "Among them, diastereomer B10 and B12 substituted (S)-2-phenylcyclopropylamide side chain of Diprovocim with simple (R)- and (S)-n-butyl groups exhibited comparable TLR2 agonistic activities with EC50 values of 35 nM and 39 nM, respectively." [PMID:36174413]; developer: "Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 201203, China." [PMID:36174413]
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Fudan Univ. TLR2 compound B10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fudan Univ. TLR2 compound B10.